127 related articles for article (PubMed ID: 7193515)
1. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Markus G; Takita H; Camiolo SM; Corasanti JG; Evers JL; Hobika GH
Cancer Res; 1980 Mar; 40(3):841-8. PubMed ID: 7193515
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.
Corasanti JG; Celik C; Camiolo SM; Mittelman A; Evers JL; Barbasch A; Hobika GH; Markus G
J Natl Cancer Inst; 1980 Aug; 65(2):345-51. PubMed ID: 6931252
[TBL] [Abstract][Full Text] [Related]
3. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Swiercz R; Wolfe JD; Zaher A; Jankun J
Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Markus G; Camiolo SM; Kohga S; Madeja JM; Mittelman A
Cancer Res; 1983 Nov; 43(11):5517-25. PubMed ID: 6193874
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
8. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Kohga S; Harvey SR; Weaver RM; Markus G
Cancer Res; 1985 Apr; 45(4):1787-96. PubMed ID: 3884145
[TBL] [Abstract][Full Text] [Related]
9. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Kinder DH; Berger MS; Mueller BA; Silber JR
Oncol Res; 1993; 5(10-11):409-14. PubMed ID: 8054701
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators in human malignant melanoma.
Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C
J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238
[TBL] [Abstract][Full Text] [Related]
12. Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Wilson EL; Becker ML; Hoal EG; Dowdle EB
Cancer Res; 1980 Mar; 40(3):933-8. PubMed ID: 7193517
[TBL] [Abstract][Full Text] [Related]
13. The plasminogen activation system in lung cancer--with special reference to the prognostic role in "non-small cell lung cancer".
Pappot H
APMIS Suppl; 1999; 92():1-29. PubMed ID: 10363031
[No Abstract] [Full Text] [Related]
14. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Bolon I; Gouyer V; Devouassoux M; Vandenbunder B; Wernert N; Moro D; Brambilla C; Brambilla E
Am J Pathol; 1995 Nov; 147(5):1298-310. PubMed ID: 7485393
[TBL] [Abstract][Full Text] [Related]
16. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
Cancer Res; 1995 Sep; 55(18):3958-63. PubMed ID: 7664262
[TBL] [Abstract][Full Text] [Related]
17. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Pyke C; Salo S; Ralfkiaer E; Rømer J; Danø K; Tryggvason K
Cancer Res; 1995 Sep; 55(18):4132-9. PubMed ID: 7664291
[TBL] [Abstract][Full Text] [Related]
18. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M
J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002
[TBL] [Abstract][Full Text] [Related]
19. Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Harvey SR; Nayak SK; Markus G; Ouhammouch M; Hemperly JJ; Dillman RO; Doyle DJ
Arch Biochem Biophys; 1997 Sep; 345(2):289-98. PubMed ID: 9308901
[TBL] [Abstract][Full Text] [Related]
20. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
